- Current report filing (8-K)
March 17 2010 - 12:08PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act 1934
Date of
Report (date of earliest event reported): March 11, 2010
American
Oriental Bioengineering, Inc.
(Exact
name of registrant as specified in charter)
Nevada
(State or
other jurisdiction of incorporation)
001-32569
|
84-0605867
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
Beijing Economic
and Technology Development Zone
1
First Liangshuihe Street
E-town,
Beijing 100176
People’s
Republic of China
(Address
of principal executive offices and zip code)
011-86-451-8666-6601
(Registrant's
telephone number including area code)
(Registrant's
former name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of registrant under any of the following
provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
5.02 Departure of Directors or Principal Officers;Election of
Directors; Appointment of Officers
On March 11, 2010 the Board
of Directors of American Oriental Bioengineering, Inc. approved the appointment
of Mr. Xiaopeng Xu as Chief Operating Officer of the Company. Mr. Xu
will succeed Ms. Yanchun Li as the Company’s Chief Operating
Officer. Ms. Li will continue to serve as the Company’s Chief
Financial Officer and as a member of the board of directors.
Since July 2009, Mr. Xu was employed by
the Company as General Manager of the AOBO Pharmaceutical Industry Co., Ltd. and
Mr. Xu will perform his current services pursuant to the employment agreement
entered into with the Company on July 15, 2009. Such
agreement may be terminated by the Company or Mr. Xu, with or without
cause. Mr. Xu will be paid an annual salary of RMB 350,000 (equal to
$51,127) and is eligible to participate in the Company’s stock and bonus
plans.
Prior to joining the Company in 2009,
Mr. Xu, has served in a number of senior positions in the pharmaceutical
industry in China, including the General Manager of China National
Pharmaceutical Industry Co., Ltd. from 2005 to 2006, Executive Deputy General
Manager of Harbin Pharmaceutical Group Co., Ltd., (Shanghai Stock Exchange:
600664) from 2004 to 2005 and the Factory Director of Harbin Pharmaceutical
Group General Industry Co., Ltd. from 1996 to 2004. Currently Mr. Xu also serves
in the following capacity for the following entities: Independent Director of
Heibei Aoxing Pharmaceutical Co., Inc. (OTC BB: CAXG), since August 2009,
Independent Director of Harbin Baida Pharmaceutical Co., Ltd. since
2005, Visiting Professor of Shenyang Pharmaceutical University since 2004, Vice
Chairman of China Pharmaceutical Industry Association since 2002, and _Vice
Chairman of China Anesthetic Association since 2003 (both of of the
latter associations are industry oriented academic
organizations). Mr. Xu graduated from Harbin CCP School in 1985 and
completed graduate level programs in CEO courses from Tsinghua University in
2002.
Mr. Xu has no family relationships with
any of the executive officers or directors of the Company. There have
been no transactions in the past two years to which the Company or any of its
subsidiaries was or is to be a party, in which he has had, or will have, a
direct or indirect material interest.
Also on
March 11, 2010, Mr. Wilfred Chow's resignation from his position as Senior Vice
President of Finance of American Oriental Bioengineering, Inc. (the “Company”)
was officially approved by the Board at its audit committee
meeting. Mr. Chow has accepted a position with another
company.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits
10.1 Executive
Employment Agreement dated as of July 15, 2009 between the Company and Xiaopeng
Xu.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
AMERICAN
ORIENTAL BIOENGINEERING, INC.
|
|
By:
/s/ Tony
Liu
|
|
Name:
Tony Liu
|
|
Title:
Chairman and Chief Executive
Officer
|
Dated: March
17, 2010
American Oriental Bioengineering, Inc. (NYSE:AOB)
Historical Stock Chart
From Jun 2024 to Jul 2024
American Oriental Bioengineering, Inc. (NYSE:AOB)
Historical Stock Chart
From Jul 2023 to Jul 2024